EyePoint, Rallybio collaboration to focus on sustained delivery of C5 inhibitor in GA
Click Here to Manage Email Alerts
EyePoint Pharmaceuticals and Rallybio have entered into a research collaboration to investigate sustained delivery of Rallybio’s complement C5 inhibitor using EyePoint’s Durasert technology.
“Rallybio’s C5 inhibitor is an affibody with high affinity to its target,” Jay S. Duker, MD, president and chief operating officer of EyePoint, told Healio/OSN. “The successful implementation of this molecule into EyePoint’s Durasert technology could allow much less frequent dosing schedules with potentially superior results due to the zero-order kinetics that is the hallmark of Durasert.”
The collaboration will initially focus on the treatment of geographic atrophy, according to a press release from EyePoint.
The companies intend to expand the collaboration, upon mutual agreement, after evaluating the viability of using the C5 inhibitor with the Durasert technology.
According to Duker, this is a timely agreement given that “blocking complement as treatment paradigm for geographic atrophy (GA) is now a proven therapeutic pathway.”
“With the FDA’s recent approval of Apellis’ C3 inhibitor, this opens up new hope for GA patients,” he said. “Rallybio and EyePoint see an opportunity to further improve the treatment paradigm by potentially permitting patients to have significantly fewer injections than the current monthly or bimonthly. This potentially could lead to even superior clinical results and better patient compliance.”
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts